Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 17, 2021
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
[ Wed, Mar 17th 2021
] - WOPRAI
Michael Morabito Maintained (AKRO) at Strong Buy with Increased Target to $81 on, Mar 17th, 2021
Michael Morabito of Chardan Capital, Maintained "Akero Therapeutics, Inc." (AKRO) at Strong Buy with Increased Target from $79 to $81 on, Mar 17th, 2021.
Michael has made no other calls on AKRO in the last 4 months.
There is 1 other peer that has a rating on AKRO. Out of the 1 peers that are also analyzing AKRO, 0 agree with Michael's Rating of Hold.
This is the rating of the analyst that currently disagrees with Michael
- Etzer Darout of "Guggenheim" Initiated at Strong Buy and Held Target at $54 on, Friday, February 26th, 2021
